Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against Spectrum Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (Nasdaq: SPPI) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.

The investigation focuses on a statement by Spectrum that it failed to disclose that the Food & Drug Administration advised it not to submit a New Drug Application for its drug candidate apaziquone back in December of 2012.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Lundin Law PCBrian Lundin, Esq.Telephone: 888-713-1033Facsimile: 888-713-1125brian@lundinlawpc.comhttp://lundinlawpc.com/

Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Spectrum Pharmaceuticals Charts.
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Spectrum Pharmaceuticals Charts.